Zhuang Weihuang, Wu Huiqiang, Cai Zhiyin, Cai Nina, Liu Weihui, Liu Wanyi
Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian, China.
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Front Oncol. 2025 Jun 12;15:1583504. doi: 10.3389/fonc.2025.1583504. eCollection 2025.
The occurrence of multiple primary prostate malignant tumors is extremely rare and there is no consensus on its diagnosis and treatment. This article presents an elderly male patient with both acinar adenocarcinoma of the prostate and small lymphocytic lymphoma (SLL) invading the prostate. He was treated with ibrutinib for the lymphoma and goserelin and bicalutamide for the prostate cancer, resulting in control of both conditions. This case highlights the complexity of diagnosing and managing multiple synchronous prostate malignancies. TP53 mutation may play a central role in dual clonal evolution. Multidisciplinary collaboration and individualized treatment plans are essential in managing rare presentations of prostate MPMT.
多发性原发性前列腺恶性肿瘤极为罕见,其诊断和治疗尚无共识。本文介绍了一名老年男性患者,患有前列腺腺泡腺癌和侵犯前列腺的小淋巴细胞淋巴瘤(SLL)。他接受了依鲁替尼治疗淋巴瘤,戈舍瑞林和比卡鲁胺治疗前列腺癌,两种病情均得到控制。该病例突出了诊断和管理多发性同步前列腺恶性肿瘤的复杂性。TP53突变可能在双重克隆进化中起核心作用。多学科协作和个体化治疗方案对于处理前列腺多原发性恶性肿瘤的罕见表现至关重要。